Covid Nasal Spray: The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19.
First nasal spray for covid-19 treatment in India: Nitric Oxide Nasal Spray (FabiSpray) will be useful in the treatment of adult patients with COVID-19 who have a high risk of progression of the disease
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. NONS was safe and well tolerated in COVID-19 patients. Glenmark